Lipitor Reimbursement Contracts Prompt Transparency Requests From Congress
This article was originally published in The Pink Sheet Daily
Pfizer’s efforts to retain market share for Lipitor have produced insurance coverage contracts expected to reduce acceptance of the generic, and that has prompted inquiries by members of Congress concerned the practice will ultimately increase drug costs to employers, Medicare and Medicaid.
You may also be interested in...
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Former CMS acting administrator Andy Slavitt says agency’s direction during Biden administration depends on nominee, but trust fund’s looming insolvency will be ‘an issue you can’t avoid.’ The president’s priorities around health equity, racial justice and mental health will make their way into CMS policy and demonstration models, Slavitt suggests.
Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.